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Background and aim: Airflow limitation may be found in patients with both asthma and COPD 
and is often associated with more symptoms and poorer outcome. We aimed to identify factors 
associated with airflow limitation in a well-characterized, population-based sample of adults.
Methods: From the Health2006 cohort, we selected participants aged $35 years at enrolment 
(n=2,959). Airflow limitation was defined as FEV
1
/FVC , lower limit of normal. Participants 
with (cases) and without (controls) airflow limitation were compared with regard to self-reported 
symptoms, medical history, atopy, lung function and exhaled nitric oxide. Between-group 
differences were analyzed using Chi-square and Mann–Whitney U tests, and effect size was 
estimated by logistic regression (reported as OR and 95% CI).
Results: We identified 313 cases, majority of which were female, reported poor overall health, 
physically inactivity and experienced respiratory symptoms within the previous year. The 
presence of airflow limitation was associated with BMI (OR 3.1 for overweight, P,0.001, 
CI 1.97–4.78), age (OR 2.3, P,0.001 for age 55+, CI 1.7–3.2), tobacco exposure (OR 1.6, 
P=0.01, CI 1.1–2.32, and OR 1.76, P=0.019, CI 1.2–2.3 for former and current smokers, 
respectively), sex (OR 1.6 for being female, P=0.002, CI 1.2–2.2), presence of specific IgE to 
common aeroallergen(s) (OR 1.4, P=0.041, CI 1.2–2.0), and ever being diagnosed with asthma 
(OR 1.6, P=0.003, CI 1.3–2.0).
Conclusion: Apart from tobacco exposure and age, the presence of airflow limitation was 
associated with being overweight, female, sensitized to common aeroallergens or ever having 
a diagnosis of asthma.
Keywords: epidemiology, cohort study, asthma, COPD, risk factors
Introduction
Chronic airways diseases are common, especially in the western world. In Denmark, 
the prevalence of COPD is 12%1 among adults $45 years of age, likewise up to 10% of 
the Danish population is prescribed medication for asthma.2 Despite traditionally being 
considered two very distinct diseases, asthma and COPD have several overlapping 
features, including the presence of airflow limitation.
In patients with asthma, more severe airflow limitation, as well as more pronounced 
bronchodilator reversibility, has been associated with higher mortality.3,4 Although 
Santibanez et al5 did not report the same association between airflow limitation and 
mortality in COPD patients, they did find an increasing risk of hospital admission for 
COPD exacerbation with higher degree of airflow limitation. Furthermore, Huang et al6 
found that airflow limitation (FEV
1
/FVC ,0.70) was independently associated with 
a higher mortality risk compared to individuals without either an asthma diagnosis or 
airflow limitation, and this risk was considerably higher in patients with both doctor-
diagnosed asthma and airflow limitation.
Correspondence: Charlotte suppli Ulrik
Department of respiratory Medicine, 
respiratory research Unit hvidovre, 
DK-2650 Hvidovre, Denmark
email csulrik@dadlnet.dk 
Journal name: International Journal of COPD
Article Designation: Original Research
Year: 2019
Volume: 14
Running head verso: Baarnes et al
Running head recto: Baarnes et al
DOI: 173815
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f C
hr
on
ic 
O
bs
tru
ct
ive
 P
ul
m
on
ar
y 
Di
se
as
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
6.
23
0.
20
0 
on
 0
9-
Ju
l-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of COPD 2019:14submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
714
Baarnes et al
Provided that airflow limitation is an indicator of poorer 
outcome, interventions that preserve current level of lung 
function and slow down the rate of deterioration could possi-
bly lead to a better prognosis. The most effective intervention 
to reduce decline of lung function is smoking cessation.7,8 
In COPD, inhaled corticosteroids (ICS) and bronchodilators 
may initially improve FEV
1
, but the effect on long-term 
decline in lung function is at best not remarkable.9–11 Treat-
ment with ICS has been shown to reduce the annual decline in 
FEV
1
,12,13 and the earlier the initiation, the better the outcome 
and the lesser the amount of ICS and additional asthma treat-
ment needed to achieve asthma control.14–16
Since time to initial treatment seems crucial for the long-
term outcome, including decline of lung function, it is of 
outmost importance to intervene as early as possible in those 
individuals at risk of developing airflow limitation. The aim 
of the present study was, therefore, to identify, especially 
modifiable, factors, associated with airflow limitation in a 
well-characterized population-based cohort of adults and by 
that, potentially facilitate future interventions, which aim at 
reducing decline in lung function in individuals at high risk.
Methods
Cohort
The Health2006 cohort comprises a sample of Danish 
adults aged 18–69 years at inclusion, at the time living 
in the south-western part of the greater the Copenhagen 
area. A total of 7,770 individuals, all Danish citizens and 
born in Denmark, were invited to participate in a general 
health examination. Of these, 3,471 (44.7%) accepted the 
invitation and were examined between June 2006 and June 
2008. The cohort has been described in detail elsewhere.17 
Participants ,35 years of age at enrolment (n=512) were 
excluded from the present analysis, as the Danish National 
Board of Health recommends screening with spirometry in 
current or former smokers, $35 years of age, with a mini-
mum of one respiratory symptom.18 This resulted in a cohort 
of 2,959 participants (Figure 1).
Questionnaire
All participants answered an extensive questionnaire 
on self-perceived health, current and previous diseases 
(including eczema, rhinitis and asthma), intolerance reac-
tions (food, alcohol, perfume and chemical substances), 
physical activity level, dietary habits, alcohol consumption, 
smoking habits, use of hormone replacement therapy after 
menopause, family and social relations, education and work 
and mental health.
Health2006 cohort
n=3,471
Excluded by age
<35 years at baseline
n=512 
Age ≥35 at baseline
n=2,959
Cases
(FEV1/FVC < LLN)
n=313
Controls
(FEV1/FVC > LLN)
n=2,646
Figure 1 Selection and categorization of participants in the Health2006 cohort for 
present analyses.
Abbreviation: lln, lower limit of normal.
anthropometric measures and obesity
Height and weight were measured with light clothing and 
without shoes, BMI calculated as weight divided by height 
squared. Hip circumference was measured over the clothing 
on the widest part of the body. Waist circumference was mea-
sured directly on the skin, between the lower ribs and the iliac 
crest. Body fat percentage was measured using impedance.
Fitness and cardiovascular function
Fitness level was measured through the Danish Step Test,19 
a test with fixed step height but increasing pace through a 
maximum of six minutes. Pulse rate and systolic and diastolic 
blood pressures were measured at rest.
sensitization to aeroallergens
Serum-specific IgE was measured for the four most com-
mon aeroallergens (birch, grass, cat and Dermatophagoides 
pteronyssinus), and classified as positive if .0.35 kU/L.20 
Skin prick testing for ten aeroallergens (birch, grass, mug-
wort, horse, dog, cat, Dermatophagoides pteronyssinus, 
Dermatophagoides farinae, Alternaria alternate and 
Cladosporium herbarum) was performed using the Soluprick 
system (ALK-Abelló A/S, Hørsholm, Denmark). Skin prick 
test reactivity was defined as a mean wheal diameter $3 mm.21
lung function
Lung function was measured according to American Thoracic 
Society’s and European Respiratory Society’s (ATS/ERS) 
standards22 with a SpiroUSB (Micro-Medical Ltd, Rochester, 
UK). Predicted FEV
1
 was calculated based on height, age 
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and sex.23 FEV
1
 and FVC are expressed as percentage of 
predicted values, FEV
1
/FVC as total percentage.
Fractional exhaled nitric oxide (FenO)
FeNO, was measured with Niox-Mino (Aerocrine AB) 
according to ATS standards.24
Definitions
The smoking status of the participants was assessed through 
the questionnaire item “Do you smoke?”, with the possible 
answers of “Yes”, “No, but I have previously smoked” and 
“No, never”. Pack-years were calculated by multiplying the 
duration (years) with intensity (grams tobacco per day, with 
one cigarette equating to 1 g, a pipe or cheroot to 3 g and 
a cigar to 5 g of tobacco). Regarding alcohol consumption, 
participants were defined as non-drinkers if they had a weekly 
consumption ,1 IU. BMI was divided into the following 
groups: underweight (,18.50), normal weight (18.5–24.99), 
overweight (25–29.99) and obese (.30).25 Airflow limita-
tion was defined as FEV
1
/FVC below the Lower Limit of 
Normal (LLN).26
statistical analyses
All analyses were done in IBM SPSS Statistics V.24 (IBM 
Corporation, Armonk, NY, USA), using 0.05 as the level of 
significance. Descriptive statistics are reported as median (IQ-
range) for non-normally distributed data. Between-group testing 
was performed using the Mann–Whitney U test for numerical 
variables and chi-squared test for ordinal and categorical vari-
ables. Univariate logistic regression was used to identify factors 
associated with airflow limitation. Multiple regression models, 
adjusted for FEV
1
 % predicted, with backward stepwise elimi-
nation was run for self-reported variables, clinical and para-
clinical variables. All variables significant in the preliminary 
analyses were combined in a final logistic regression model, 
and findings were reported as OR with 95% CI.
ethics statement
The Health2006 cohort was approved by the Ethical Com-
mittee of Copenhagen County (ID KA20060011). All 
participants provided written informed consent.
Results
Due to limitation of space, not all results are reported. Non-
reported results were non-significant, including, but not 
limited to, waist and hip circumference and blood pressure 
(these results are available upon request).
Cohort characteristics
Present analysis included 2,959 participants (46% men 
and mean age 54 years at inclusion). A total of 61% were 
ex- or current smokers, and mean FEV
1
 97.8% of predicted. 
(Tables 1 and 2)
Comparison of cases and controls
Airflow limitation was found in 313 individuals (10.6%), 
mean age 52.0 years, 37.4% men. Participants with airflow 
limitation were, as expected, more likely to be ever smokers 
(80.2%) and have a lower mean FEV
1
 (83.0% of predicted) 
compared to controls, ie, participants without airflow limita-
tion. Further details are given in Tables 1 and 2.
Factors associated with airflow limitation
The variables associated with the highest odds ratio for air-
flow limitation were increasing age (OR 2.08 [CI 1.29–3.37] 
and OR 2.29 [CI 1.66–3.15] for age 41–55 and .55 years, 
respectively), being overweight (OR 3.07 [CI 1.97–4.78]) 
and a history of tobacco smoking (OR 1.76 [CI 1.18-2-25] 
and OR 1.62 [CI 1.12–2.34] for current and former smokers, 
respectively). Further results are given in Table 3.
Discussion
The current study provides details on self-reported and 
clinical characteristics of participants with or without airflow 
limitation and identifies a number of variables associated 
with an increased risk of presenting with airflow limitation.
One reason no association between FeNO and airflow 
limitation was found could be the lower FeNO in our case 
group due to the larger number of current smokers, as smoking 
is associated with lower levelse of FeNO.27 Ten Brinke et al28 
found a small, but significant, association between airflow 
limitation and FeNO (OR 1.7 for FeNO .10 ppb), but their 
cut-off value was low, compared to the 95th percentile value 
of 39 ppb found in healthy subjects in National Health and 
Nutrition Examination Survey (NHANES).29 Bommarito 
et al30 reported that a high FeNO was significantly associated 
with a high risk of asthma as well as a negative association 
between smoking and FeNO. Matsunaga et al31 found FeNO 
to be a specific, though not very sensitive, marker for rapid 
decline of lung function. They also observed that a suppression 
of FeNO was associated with an improvement in airflow limi-
tation.32 In contrast, Tay et al33 found no association between 
FeNO and chronic airflow limitation in patients with asthma.
Tobacco smoking is the most important risk factor for 
COPD development.34 Thus, the higher risk of airflow limita-
tion associated with smoking was not an unexpected finding in 
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Table 1 Self-reported characteristics of participants in the Health2006 study according to presence (cases) or absence (controls) of 
airflow limitation
Controls n=2,646 Cases n=313 P-value
smoking habits
Current smokers, % 22.4 41.9 ,0.001
never-smokers, % 41.3 19.8 ,0.001
Pack years 19.5 (19.0) 26.0 (25.7) ,0.001
alcohol consumption
non-drinkers, % 5.6 6.7 ns
Weekly consumption, unitsa 8.0 (11.0) 8.0 (11.0) ns
10 years of school or less, % 10.1 13.7 ns
hormone replacement treatment (women only)
Yes, % 34.9 35.8 ns
number of years 7.0 (8.0) 5.0 (8.0) ns
symptoms last 12 months
rhinitis, % 51.9 56.1 ns
asthma symptoms, % 2.5 17.0 ,0.001
Dyspnoea at rest, % 26.9 48.5 ,0.001
Dyspnoea during activity, % 6.5 10.0 0.021
Chronic bronchitis,b % 8.3 22.3 ,0.001
nightly respiratory symptoms, % 16.0 23.1 0.002
Wheezing, % 19.6 43.4 ,0.001
ever diagnosed with
rhinitis, % 17.4 22.3 0.034
asthma, % 8.8 20.9 ,0.001
eczema, % 4.5 7.0 ns
hypertension, % 31.4 30.1 ns
Diabetes, % 4.4 4.5 ns
hyper-cholesterolaemia, % 34.7 30.5 ns
self-ratedc
Overall health (1–5), mean (sD) 2.5 (0.8) 2.7 (0.9) ,0.001
exercise habits (1–5), mean (sD) 3.2 (1.0) 3.4 (1.0) 0.013
Dietary habits (1–5), mean (sD) 2.7 (0.6) 2.7 (0.6) ns
social position (1–5), mean (sD) 2.7 (0.6) 2.7 (0.6) ns
Notes: Using Chi-square and Mann-Whitney U-test. Unless otherwise stated, numbers are reported as median (IQ-range). aCalculated for people who reported a current 
alcohol consumption only. bself-reported cough with sputum for at least 3 months/year for at least two consecutive years. cMeasured on a scale from 1 to 5, where 1 is best.
Abbreviation: NS, not significant.
this study. Nakao et al35 found OR of 1.91 for current smokers 
compared to never smokers, but no increased risk for former 
smokers, contrasting with our findings. However, the number 
of former smokers in their study was quite small, 9%, com-
pared to our 36% of controls and 38% of cases, making it more 
difficult to show smaller differences between groups. Both 
active and passive tobacco smoking is associated with more 
symptoms, lower lung function, lower quality of life and a 
worse outcome for patients with asthma.36 Though it could be 
argued that our finding of increased risk of airflow limitation 
with increasing tobacco consumption is a risk for developing 
COPD only, the fact that we also found an increased risk with 
both atopy and ever having had asthma, indicates that the 
higher OR related to smoking habits is for airflow limitation 
in general, not only for COPD in its traditional definition.34
Previous cluster analyses have described two obesity-
related phenotypes of asthma, early- and late onset.37 While 
early-onset asthma is often allergic, and made worse by 
obesity, late-onset is predominantly non-atopic, most often 
seen in women, and could be due to both local and systemic 
inflammatory effects of obesity.38 In line with our findings, 
Nakao et al35 found high BMI to be an independent predictor 
of airflow limitation (adjusted OR 2.05 for BMI .25). In 
contrast, Colak et al39 found that a high BMI reduced the 
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Table 2 Clinical characteristics of participants in the Health2006 
study according to presence (cases) or absence (controls) of 
airflow limitation
Controls 
n=2,646
Cases 
n=313
P-value
sex, % men 46.5 37.4 0.002
age, years 52.0 (17.0) 52.0 (15.0) ns
BMIa (kg/m2) 25.3 (5.0) 24.6 (5.0) ,0.001
normal or underweight, % 43.3 54.5 ,0.001
Overweight, % 39.1 33.0 0.035
Obese, % 17.6 12.5 0.021
Fat percentage, % 29.2 (13.0) 30.0 (14.0) ns
FeV1, % predicted 101.0 (18.0) 83.0 (19.0) ,0.001
FVC, % predicted 105.0 (19.0) 106.0 (25.0) ns
FeV1/FVC, % 79.5 (7.0) 65.8 (7.0) ,0.001
FenO, ppb 16.0 (13.0) 14.0 (14.0) ,0.001
Fitness level, mlO2/kg/min 30.0 (11.0) 28.0 (12.0) ns
Positive skin prick test, % 27.9 27.9 ns
Positive Ige,b % 21.8 19.3 ns
systolic blood pressure, mmhg 124.0 (21.0) 128.5 (22.0) ns
Notes: Using Chi-square and Mann-Whitney U-test. Unless otherwise stated, 
numbers are reported as median (IQ-range). Values in parentheses are IQ-range 
for the mean values. aBMI: Body mass index, using following categories: normal 
or underweight (#24.9), overweight (25.0–29.9), obese ($30.0). FeV1: Forced 
expiratory volume in 1 second. FVC: Forced vital capacity. FenO: Fractional exhaled 
nitric oxide. bIge: mmunoglobulin e. Positive for at least one of the four tested 
allergens: cat, grass, house dust mites and birch.
Abbreviation: NS, not significant.
Table 3 Factors associated with airflow limitation in the 
Health2006 cohort reported as odds ratios
OR 95% CI P-value
sexa 1.61 1.20–2.16 0.002
BMIb
Overweight 3.07 1.97–4.78 ,0.001
Obese 1.70 1.08–2.68 0.023
agec
41–55 years 2.08 1.29–3.37 0.003
.55 years 2.29 1.66–3.15 ,0.001
Positive specific IgE to aeroallergensd 1.44 1.18–1.98 0.041
ever asthma 1.57 1.32–2.02 0.003
smoking habitse
Current smoker 1.76 1.18–2.25 0.019
Former smoker 1.62 1.12–2.34 0.010
Notes: adjusted for FeV1. 
aOr for women, compared to men. bBMI: Body mass 
index. reference group normal/underweight. cCompared to age ,41 years. dIge: 
Immunoglobulin e. Positive for at least one of the four tested allergens: cat, grass, 
house dust mites and birch. eCompared to never-smokers.
probability of airflow limitation, defined as FEV
1
/FVC ,0.70 
(adjusted OR 0.63 for BMI 25–29.9, adjusted OR 0.50 for 
BMI .35), the results remaining the same when defining 
airflow limitation as FEV
1
/FVC , LLN. Others found that for 
a given BMI quartile, lung function was negatively associated 
with increasing waist to hip ratio, but less clearly directly 
associated with increasing BMI.40 The effect was stronger in 
men than in women, possibly due to differences in distribu-
tion of adipose tissue between sexes. Obese women often 
have a smaller waist to hip ratio as the adipose tissue accu-
mulates on the hip and thighs,41 while men tend to develop 
abdominal obesity, which has an extra-thoracic restrictive 
effect on lung volumes.42 Boulet & Des Cormiers43 found 
self-reported asthma to increase linearly with BMI, though 
mostly evident in women with BMI of $30, and for men 
only with BMI of $40. The difference might be due to the 
heterogeneity of our participants, as Boulet and Des Corm-
iers43 focused on asthma, not airflow limitation in general.
Overall, the number of women with respiratory disease, 
including COPD and lung cancer, has increased. The higher 
risk of airflow limitation for women may be due to women 
having caught up on the habit of smoking in the last decades, 
or it may simply be that women’s lungs, being smaller than 
men’s, are more vulnerable to damage.
Conclusion
The present study showed that being females, being over-
weight, a history of ever having received a diagnosis of 
asthma and sensitization to common aeroallergens, together 
with tobacco exposure and increasing age, were associated 
with the presence of airflow limitation. Longitudinal stud-
ies are required to determine causality and to identify risk 
factors most suited for intervention to prevent loss of lung 
function over time.
Disclosure
The authors report no conflicts of interest in this work.
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